Multidrug-resistant tuberculosis (MDR-TB): an evolving threat to the Nigerian health system – a review
Authors:
- Aminu ShehuASAminu Shehu
- Malik Olatunde OduoyeMOMalik Olatunde Oduoye
- Araj Naveed SiddiquiASAraj Naveed Siddiqui
- Hareem ShaikhHSHareem Shaikh
- Janice OdhiamboJOJanice Odhiambo
- Muhammad MuhsinMMMuhammad Muhsin
- Abdullahi Zainab ZubairuAZAbdullahi Zainab Zubairu
- Chidiogo EzenwobaCEChidiogo Ezenwoba
- Ahmad AbdulhadiAAAhmad Abdulhadi
- Chrispin BiambaCBChrispin Biamba
- Laiba ShakeelLSLaiba Shakeel
- Amidu AlhassanAmidu Alhassan
Open Access
- 18 November 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 443-450
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is an increasing public health issue that threatens the efforts in the treatment and control of tuberculosis (TB) worldwide, including in Nigeria. According to the World Health Organization, there were 558 000 MDR-TB cases globally in 2019. Nigeria, being the most populous country in Africa, is said to carry a larger proportion of MDR-TB in the world. If not addressed promptly, many Nigerian populations will continue to suffer from MDR-TB, which could result in increased morbidity and mortality rates. Eliminating the threat of MDR-TB in Nigeria requires a multifaceted approach that combines national and international efforts. These approaches should be centered on the molecular testing of MDR-TB using line probe assays and GeneXpert MTB/RIF technology, which enables early and efficient diagnosis of Mycobacterium tuberculosis and TB drug resistance among patients in high-risk populations. Improvements can occur through the development and implementation of new treatment therapies and investment in research to discover additional treatment options for TB. Public awareness and education about the disease are also important. If these recommendations are implemented, they can significantly decrease the burden of MDR-TB in Nigeria.Keywords
This publication has 26 references indexed in Scilit:
- Epidemiology and molecular characterization of multidrug-resistant Mycobacterium tuberculosis among patients with pulmonary symptoms in Kaduna State, NigeriaActa Tropica, 2025
- Stigma experienced by people with drug-resistant tuberculosis in Lagos, Nigeria: a cross-sectional studyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2025
- A four-drug standardized short regimen for highly resistant TB in South-West NigeriaInternational Health, 2023
- Antimicrobial resistance in Nigeria: challenges and charting the way forwardEuropean Journal of Hospital Pharmacy, 2022
- Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosisEuropean Respiratory Journal, 2019
- Pyridines: Multidrug-resistant tuberculosis (MDR-TB) inhibitorsIndian Journal of Tuberculosis, 2017
- The Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-AnalysisPLOS ONE, 2016
- Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in NigeriaPLOS ONE, 2014
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic ReviewPLOS ONE, 2009